Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-Coinfected patients

被引:29
|
作者
Larrousse, Maria
Laguno, Montserrat
Segarra, Marta
De lazzari, Elisa
Martinez, Esteban
Blanco, Dose Luis
Leon, Agathe
Deulofeu, Ramn
Miquel, Rosa
Milinkovic, Ana
Lonca, Montserrat
Miro, Jose Maria
Biglia, Alejandra
Murillas, Javier
Gatell, Jose Maria
Mallolas, Josep
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Infect Dis Unit, IDIBAPS, E-08036 Barcelona, Spain
[2] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Serv Biochem, Barcelona, Spain
[3] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Pathol Serv, Barcelona, Spain
关键词
noninvasive diagnosis of hepatic fibrosis; HIV/HCVcoinfected; patients; tissue inhibitors of matrix metalloprotemases; (TIMP-1); hyaluronic acid (HA);
D O I
10.1097/QAI.0b013e3181520502
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Several serum markers reflecting extracellular matrix status have been correlated with liver fibrosis in non-HIV-infected patients with chronic hepatitis C infection. These indexes have been less examined in HIV/HCV-coinfected individuals. alternative to liver biopsy when the degree of liver fibrosis needs to be estimated. Objective: We aimed to evaluate the predictive value of serum markers for liver fibrosis in non-HIV-infected patients with chronic hepatitis C virus (HVC). Methods: Serum levels of metalloproteinases I and 2 (MMP-1 and -2), tissue inhibitors of matrix metalloprotemases (TIMP-1), procollagen type III N-terminal peptide (PIIINP), and hyaluronic acid (HA) were measured in non-HIV-infected patients with chronic hepatitis C at the time of obtaining a liver biopsy and before the consideration of anti-hepatitis C therapy. Results: One hundred and nineteen consecutive HIV-HVC coinfected patients were included. TIMP-1 (r = 0.6; P < 0.001), TIMP-1/MMP-1 ratio (r = 0.5; P < 0.001), TIMP-1/MMP-2 ratio (r = 0.3; P < 0.001), MMP-2 (r = 0.2; P = 0.044), PIIINP (r = 0.4; P < 0.00 1), and HA (r = 0.5; P < 0.001) were positively and significantly correlated with the fibrosis stage. In the multivariate analysis, TIMP-1 (odds ratio [OR] = 1.004, 95% confidence interval [Cl]: 1.002 to 1.006, P = 0.00 1) and HA >95 mu g/dL (OR = 6.041, 95% Cl: 1.184 to 30.816, P = 0.03 1) were independently associated with liver fibrosis. The area under the curve of score to discriminate mild (FO-FI) from significant (F2-F4) fibrosis in the received-operating analysis using the variables TIMP-1 and HA was 0.84, with a sensitivity of 72.9% and a specificity of 83.1 %. Conclusion: TIMP-I and HA were quite sensitive and specific for predicting the degree of liver fibrosis in non-HIV-infected patients with chronic hepatitis C. These parameters may become a noninvasive alternative to liver biopsy when the degree of liver fibrosis needs to be estimated.
引用
收藏
页码:304 / 311
页数:8
相关论文
共 50 条
  • [31] Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients
    Terrier, Benjamin
    Costagliola, Dominique
    Besson, Caroline
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 (02) : E86 - E87
  • [32] Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients
    Núñez, M
    Soriano, V
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (01): : 1 - 3
  • [33] European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain
    Tabernilla, Andres
    Rego-Perez, Ignacio
    Grandal, Marta
    Pernas, Berta
    Pertega, Sonia
    Delgado, Manuel
    Marino, Ana
    Alvarez, Hortensia
    Mena, Alvaro
    Rodriguez-Osorio, Iria
    Domingo Pedreira, Jose
    Javier Blanco, Francisco
    Poveda, Eva
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (02) : 149 - 153
  • [34] The HIV/HCV-Coinfected Patient and New Treatment Options
    Vachon, Marie-Louise C.
    Dieterich, Douglas T.
    [J]. CLINICS IN LIVER DISEASE, 2011, 15 (03) : 585 - +
  • [35] Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV
    James S. Park
    Neeraj Saraf
    Douglas T. Dieterich
    [J]. Current Hepatitis Reports, 2005, 4 (2) : 68 - 74
  • [36] Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy
    Labarga, P.
    Fernandez-Montero, J. V.
    Barreiro, P.
    Pinilla, J.
    Vispo, E.
    de Mendoza, C.
    Plaza, Z.
    Soriano, V.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2014, 21 (07) : 475 - 479
  • [37] A simple noninvasive index can predict significant fibrosis in HIV-HCV coinfected patients
    Sterling, RK
    Fung, SK
    Marrero, JA
    Wilson, MS
    Stravitz, RT
    Luketic, VA
    Sanyal, AJ
    Contos, MJ
    Mills, AS
    Shiffman, ML
    Lok, ASF
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A744 - A744
  • [38] Insulin Resistance Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients
    Ryan, Pablo
    Berenguer, Juan
    Michelaud, Dariela
    Miralles, Pilar
    Bellon, J. M.
    Alvarez, Emilio
    Catalan, Pilar
    Sanchez-Conde, Matilde
    Resino, Salvador
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (01) : 109 - 110
  • [39] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
    Perez-Latorre, Leire
    Sanchez-Conde, Matilde
    Miralles, Pilar
    Carlos Lopez, Juan
    Parras, Francisco
    Tejerina, Francisco
    Aldamiz-Echevarria, Teresa
    Carrero, Ana
    Diez, Cristina
    Ramirez, Margarita
    Gutierrez, Isabel
    Maria Bellon, Jose
    Banares, Rafael
    Berenguer, Juan
    [J]. BMC INFECTIOUS DISEASES, 2018, 18
  • [40] Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients
    Laguno, M
    Milinkovic, A
    de Lazzari, E
    Murillas, J
    Martínez, E
    Blanco, JL
    Loncá, M
    Biglia, A
    Leon, A
    García, M
    Larrousse, M
    García, F
    Miró, JM
    Gatell, JM
    Mallolas, J
    [J]. ANTIVIRAL THERAPY, 2005, 10 (03) : 423 - 429